| MYLAN, INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20160331694 | FENOFIBRATE FORMULATION - Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. The mass ratio of the drug to the binder in the dosage form is between about 3.5:1 and 4.5:1; and the dosage form produces a first Cmax in vivo that is between about 10% and about 50% higher than a comparative Cmax produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of between about 5:1 and 15:1. | 11-17-2016 |
| 20160157816 | DEVICE FOR DETECTING MUSCLE DEPTH AND METHOD - The hand-held device detects the distance between a muscle and an outer skin layer in a body by impacting the outer surface of the skin and detecting the distance to the muscle from that point of engagement. The device includes a first end including a force sensor configured to detect the force of an impact of the first end to an associated body part. The device further includes a distance sensor provided at the first end configured to detect the distance between a skin outer layer and a muscle; and a main body configured to receive a hand. The detection device includes a controller and processor to detect the impact force and distance between the skin outer layer and muscle at engagement. The device may be used in a method of determine muscle depth and/or location in connection with the prescription and/or administration of anaphylaxis medications by auto injector. | 06-09-2016 |
| 20160051494 | MULTI-DOSE MEDICATION KIT FOR TREATING ANAPHYLAXIS - Various exemplary embodiments relate to an emergency medicament component. The multi-dose medication kit includes a first medication administration component including a first element having first dosage of epinephrine administered by intramuscular or subcutaneous administration. The multi-dose medication kit further includes second medication administration component including a second element, having a second dosage of a β-agonist provided in a dosage which is effective to treat symptoms of anaphylaxis. | 02-25-2016 |
| 20150258037 | TRANSDERMAL DOSAGE FORM FOR LOW-MELTING POINT ACTIVE AGENT - A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. The hydrophobic reservoir layer may serve as a skin-contacting adhesive layer. Alternatively, a release-controlling adhesive layer may serve as the skin-contacting adhesive layer. The release-controlling adhesive layer may contain hydrophobic colloidal silica and a mixture of polyisobutylene and mineral oil. | 09-17-2015 |
| 20150118317 | FENOFIBRATE FORMULATION - Various fenofibrate dosage forms contain a plurality of beads or particles, where the beads or particles include a pharmaceutical composition comprising fenofibrate; from 0.3% to 10% by weight of the beads or particles of a surfactant; and from about 5% to about 15% by weight of the beads or particles of a water soluble or water dispersible cellulosic binder. The mass ratio of the drug to the binder in the dosage form is between about 3.5:1 and 4.5:1; and the dosage form produces a first Cmax in vivo that is between about 10% and about 50% higher than a comparative Cmax produced by a comparative dosage form. The comparative dosage form comprises the drug and the binder in a ratio of between about 5:1 and 15:1. | 04-30-2015 |
| 20150078536 | SYSTEM AND METHOD FOR MEDICAMENT STORAGE, DISPENSING, AND ADMINISTRATION - Various exemplary embodiments relate to a medicament storage case including: a case body securable to a wall; a door connected to the body; a sleeve to contain an epinephrine injector; a medicament lock including a hook, wherein the hook is positioned to engage the sleeve when in a first position and is positioned to disengage the sleeve when in a second position; an actuator including a solenoid, wherein the solenoid, upon activation, moves the hook from the first position to the second position; a microphone configured to receive first audio as input; a speaker configured to output second audio; a communication unit configured to provide Internet connectivity; a button; and a processor configured to: in response to pressing the button: establish communication between the local user and a remote site, receive an unlock message, and in response to receiving the unlock message, activate the solenoid to release of the sleeve. | 03-19-2015 |
| 20150024045 | LIQUID-FILLED HARD GEL CAPSULE PHARMACEUTICAL FORMULATIONS - Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight long chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides, wherein the long chain triglycerides and medium chain mono/diglycerides are present at a ratio by weight of from about 10:1 to about 5:1. | 01-22-2015 |
| 20140379874 | MEDICATION DELIVERY SYSTEM AND METHOD - A medication delivery system includes a medical server configured to send and receive and process data, a medication device configured to administer a preselected medication, a sensor circuit configured to detect selected parameters relating to medication delivery and transmit information, a transmission hub configured to communicate with the medical server and the sensor circuit. The transmission hub is configured to receive a signal from the sensor circuit and exchange the information. An application is configured to facilitate exchange of information between the sensor circuit and the medical server. The application has a preselected set of protocols. The application monitors usage of the medication device and location of the medication device by connecting to the medication device via the transmission hub. | 12-25-2014 |
| 20140357304 | MEDICAMENT INFORMATION SYSTEM AND METHOD - Various exemplary embodiments relate to a method, device, and storage medium including one or more of the following: receiving location information and expiration information; determining a current location of the mobile device; determining that the medicament device is within a predetermined distance from the mobile device; determining that the medicament device is currently associated with an expiration event; outputting an expiration alarm indicating the expiration event in response to determining that the medicament device is within a predetermined distance from the mobile device and that the medicament device is currently associated with an expiration event; receiving, from the user, a request to display a map of a geographic area; displaying, by the mobile device and via a non-operating system application, the map of the geographic area; and displaying an alert icon on the map, wherein the location of the icon on the map is based on the received location information. | 12-04-2014 |
| 20140272987 | GLATIRAMER ACETATE RESPONSE BIOMARKER mRNA POTENCY ASSAY - The invention describes assays for determining the potency of a test lot of glatiramer acetate (GA) by quantitating and comparing the levels of mRNA response biomarkers produced in mouse T-cells in response to stimulation with the test lot or a reference standard lot of GA, wherein the T-cells are obtained from mice immunized with the test lot or the reference standard lot of GA. Methods for identifying mRNA response biomarkers useful in the assays of the invention also are described. | 09-18-2014 |
| 20140252927 | SYSTEM AND METHOD FOR MEDICAMENT STORAGE, DISPENSING, AND ADMINISTRATION - Various exemplary embodiments relate to a medicament storage case including: a case body securable to a wall; a door connected to the body; a sleeve to contain an epinephrine injector; a medicament lock including a hook, wherein the hook is positioned to engage the sleeve when in a first position and is positioned to disengage the sleeve when in a second position; an actuator including a solenoid, wherein the solenoid, upon activation, moves the hook from the first position to the second position; a microphone configured to receive first audio as input; a speaker configured to output second audio; a communication unit configured to provide Internet connectivity; a button; and a processor configured to: in response to pressing the button: establish communication between the local user and a remote site, receive an unlock message, and in response to receiving the unlock message, activate the solenoid to release of the sleeve. | 09-11-2014 |
| 20140188057 | TRANSDERMAL DOSAGE FORM FOR LOW-MELTING POINT ACTIVE AGENT - A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. | 07-03-2014 |
| 20140179784 | LEVOTHYROXINE FORMULATION WITH CARRAGEENAN - A pharmaceutical composition comprising thyroxine and carrageenan. The pharmaceutical composition has an improved shelf life compared to other pharmaceutical compositions containing thyroxine. In one embodiment, the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol. The pharmaceutical composition may be used for treating thyroid disorders by orally administering the composition to a patient in need thereof. | 06-26-2014 |
| 20140179740 | STABLE LIQUID REMIFENTANIL FORMULATIONS - A stable, non-aqueous, liquid pharmaceutical composition contains remifentanil dissolved in a non-aqueous solvent. The formulation is provided with a pH ranging from about 2.0 to about 3.5 and can be used as an injectable. A method for preparing the formulation is also provided. | 06-26-2014 |
| 20140178511 | LEVOTHYROXINE FORMULATION WITH ACACIA - A pharmaceutical composition comprising thyroxine, acacia, and an antioxidant selected from propyl gallate, butylated hydroxyanisol, and butylated hydroxytoluene is disclosed. The pharmaceutical composition has an improved shelf life. In one embodiment, the composition additionally comprises sucrose, microcrystalline cellulose, and mannitol. The pharmaceutical composition may be used for treating thyroid disorders by orally administering the composition to a patient in need thereof. | 06-26-2014 |
| 20140155827 | MEDICAMENT INFORMATION SYSTEM AND METHOD - Various exemplary embodiments relate to a method of using an emergency medicament device. The method includes reading an ID tag from the medicament device using a mobile device; automatically requesting instructions for using the medicament device based on the ID tag; and displaying a video to a user of the mobile device, the video providing instructions for using the medicament device in accordance with approved labeling of the medicament device. Various exemplary embodiments relate to an electronic medicament device including: a reservoir configured to store an amount of medication for treating anaphylaxis; an administration component for administering the medication to a patient; a processor communicatively connected to a memory storing medicament device information; and an identification tag configured to be read by another device, the identification tag providing the medicament device information including identification of instructions for using the medicament device. | 06-05-2014 |
| 20140083878 | TRANSDERMAL DRUG DELIVERY DEVICE - A transdermal drug delivery device is disclosed for administering an oxidizably and/or hydrolyzably degradable drug, e.g., cholinesterase inhibitors such as rivastigmine. The device comprises a) a substantially impermeable backing layer; b) an adhesive layer substantially free of antioxidant and containing a therapeutically effective amount of the degradable drug, which adhesive drug-containing layer is capable of adhering directly to a subject's skin or to another adhesive layer which is capable of adhering to a subject's skin; and c) a substantially impermeable protective release liner layer which releasably contacts the adhesive drug-containing layer or another adhesive layer. The delivery device is sealed in a degradation protective packaging system, such as a substantially oxygen impermeable heat sealable plastic pouch that contains a substantially inert gas and/or a degradation protectant material for the drug, such as an antioxidant, which can be inserted separately to the pouch. A method of making the device is also provided. | 03-27-2014 |
| 20140045801 | PRAMIPEXOLE TRANSDERMAL DELIVERY FOR SEVERE HEADACHES - The present invention relates to a method for the treatment and prevention of cluster headaches and migraines using the transdermal administration of pramipexole. | 02-13-2014 |
| 20130344155 | FENOFIBRATE FORMULATION - Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative. | 12-26-2013 |
| 20130129822 | LIQUID-FILLED HARD GEL CAPSULE PHARMACEUTICAL FORMULATIONS - Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight medium chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides, wherein the medium chain triglycerides and medium chain mono/diglycerides are present at a ratio by weight of from about 10:1 to about 5:1. | 05-23-2013 |
| 20120078204 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled. | 03-29-2012 |
| 20110280967 | DISINTEGRABLE FORMULATIONS OF LANTHANUM CARBONATE - Disintegrable preparations of lanthanum carbonate prepared by co-precipitation, facilitating the manufacture of oral pharmaceutical dosage forms such as tablets, capsules, powders, granules, and sprinkles, and the use of such dosage forms to treat subjects with hyperphosphatemia are disclosed. | 11-17-2011 |
| 20110020426 | PROCESS FOR THE CONTINUOUS MANUFACTURE OF A POLYISOBUTYLENE BASED TRANSDERMAL PATCH - The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient. | 01-27-2011 |
